ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ICPT Intercept Pharmaceuticals Inc

19.00
0.00 (0.00%)
06 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Intercept Pharmaceuticals Inc NASDAQ:ICPT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 19.00 18.66 19.02 0 01:00:00

Intercept to Present at Upcoming Investor Conference

09/12/2016 10:00pm

GlobeNewswire Inc.


Intercept Pharmaceuticals (NASDAQ:ICPT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Intercept Pharmaceuticals Charts.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced management will be participating in following investor conference:

  • BMO Prescriptions for Success Healthcare Conference on December 14, 2016 at 1:00 p.m. Eastern Time

Webcast information for this event will be available on the Investors page of Intercept's website at http://ir.interceptpharma.com. Archived webcasts will be available on Intercept's website for approximately two weeks.

About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept now has operations in the United States, Europe and Canada.

For more information about Intercept Pharmaceuticals, please contact:

Intercept Pharmaceuticals:
Mark Vignola
+1-646-747-1000
investors@interceptpharma.com

Media inquiries: media@interceptpharma.com

Investor inquiries: investors@interceptpharma.com

1 Year Intercept Pharmaceuticals Chart

1 Year Intercept Pharmaceuticals Chart

1 Month Intercept Pharmaceuticals Chart

1 Month Intercept Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock